Vawter Financial Ltd. Reduces Holdings in Johnson & Johnson (NYSE:JNJ)

Vawter Financial Ltd. lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 4.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,289 shares of the company’s stock after selling 150 shares during the period. Vawter Financial Ltd.’s holdings in Johnson & Johnson were worth $476,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Bank of Jackson Hole Trust acquired a new position in shares of Johnson & Johnson in the fourth quarter worth $1,176,000. Lorne Steinberg Wealth Management Inc. increased its position in Johnson & Johnson by 0.6% during the 4th quarter. Lorne Steinberg Wealth Management Inc. now owns 31,976 shares of the company’s stock worth $4,624,000 after purchasing an additional 198 shares in the last quarter. Callahan Advisors LLC raised its stake in Johnson & Johnson by 3.8% in the 4th quarter. Callahan Advisors LLC now owns 122,709 shares of the company’s stock valued at $17,746,000 after purchasing an additional 4,467 shares during the last quarter. Mcdonald Partners LLC lifted its holdings in Johnson & Johnson by 4.8% in the 4th quarter. Mcdonald Partners LLC now owns 27,413 shares of the company’s stock valued at $3,965,000 after purchasing an additional 1,246 shares in the last quarter. Finally, Hara Capital LLC boosted its stake in shares of Johnson & Johnson by 13.4% during the 4th quarter. Hara Capital LLC now owns 2,560 shares of the company’s stock worth $370,000 after purchasing an additional 303 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Trading Up 1.7 %

JNJ opened at $162.35 on Friday. The firm’s 50 day moving average is $148.93 and its 200-day moving average is $155.90. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $390.87 billion, a P/E ratio of 24.41, a P/E/G ratio of 2.53 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.29 EPS. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.06%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on JNJ shares. Guggenheim upped their price objective on shares of Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Wells Fargo & Company decreased their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Wolfe Research initiated coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Raymond James decreased their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Finally, Bank of America dropped their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.